. 2023 Oct 27;20(10):e1004304. doi: 10.1371/journal.pmed.1004304

Table 1. Age-specific HPV type distribution of invasive cervical cancer cases by screening status in last 10 years.

	Age <30 years		Age 30–39 years		Age 40–49 years		Age 50–64 years		Age > = 65 years
	N	%^d	N	%^d	N	%^d	N	%^d	N	%^d
Cases that were screened in the last 10 years
HPV 16	81	63.3	305	59.2	208	48.3	197	47.0	70	42.7
HPV 18	34	26.6	121	23.5	98	22.7	73	17.4	17	10.4
HPV 45	4	3.1	36	7.0	39	9.0	40	9.5	4	2.4
Intermediate oncogenic types^a	8	6.3	30	5.8	29	6.7	29	7.0	24	14.6
Lower oncogenic types^b	1	0.8	9	1.8	21	4.9	13	3.0	5	3.0
Oncogenic HPV negative^c	0	0.0	14	2.7	36	8.4	67	16.0	44	26.8
Total	128	100	515	100	431	100	419	100	164	100
Cases that were unscreened in the last 10 years
HPV 16	29	74.4	69	69.0	80	58.0	135	54.7	297	44.4
HPV 18	6	15.4	15	15.0	26	18.8	29	11.7	51	7.6
HPV 45	3	7.7	6	6.0	10	7.2	24	9.7	31	4.6
Intermediate oncogenic types^a	1	2.6	6	6.0	9	6.5	26	10.4	105	15.6
Lower oncogenic types^b	0	0.0	2	2.0	3	2.1	14	5.6	51	7.4
Oncogenic HPV Negative^c	0	0.0	2	2.0	10	7.2	19	7.7	134	20.0
Total	39	100	100	100	138	100	247	100	669	100

^aIntermediate oncogenic types include HPV 31, 33, 52, 58 (etiological fraction>2% according to IARC’s data [4]).

^bLower oncogenic types include HPV 35, 39, 51, 56, 59, 66, 68 (etiological fraction <2% according to IARC’s data [4]).

^cOncogenic HPV negative in formalin-fixed paraffin-embedded tumor blocks.

^dColumn percentage: number of cases of a certain type divided by all cases (oncogenic HPV negative cases included in the denominator).

HPV, human papillomavirus; IARC, International Agency for Research on Cancer.